Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant Recruiting Phase 2 Trials for Gemcitabine (DB00441)

IndicationStatusPhase
DBCOND0115402 (Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03912818Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder CancerTreatment